Hematologic Oncology Update Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Nov 13, 2025
Dr. Matthew Lunning, an expert in B-cell lymphomas, discusses CAR T-cell therapy's logistics and its efficacy against standard care in high-risk diffuse large B-cell lymphoma (DLBCL). Alongside him, Dr. Sonali M. Smith, a senior lymphoma investigator, shares insights on frontline and relapsed treatments for DLBCL and follicular lymphoma. They explore the potential of bispecific antibodies, comparing their effectiveness, patient suitability, and safety in various scenarios. Their conversation reveals the evolving strategies and personalized approaches in lymphoma treatment.
AI Snips
Chapters
Transcript
Episode notes
CAR-T Requires A Pit Crew
- CAR-T delivery requires a multidisciplinary team and complex logistics from community to authorized centers.
- Financial and pre/post-apheresis barriers cause many patients to drop out before receiving CAR-T.
CAR-T Beats Real-World Salvage
- Zuma-7 and TRANSFORM showed CAR-T improves event-free survival versus real-world standard care including platinum salvage ± transplant.
- Earlier referral to CAR-T (for poor responders to frontline) may improve outcomes but overall survival benefit varied by subgroup.
CR Predicts Durability In Follicular Lymphoma
- In follicular lymphoma CAR-T yields high CR rates, and achieving CR predicts durability.
- Durability matters far more in FL, so timing of CAR-T is critical.